Anixa Biosciences' Breast Cancer Vaccine Safe, Well Tolerated In Phase 1 Study

Anixa Biosciences reported final Phase 1 results for its alpha-lactalbumin (aLA) breast cancer vaccine, showing the trial met all primary endpoints, was safe and well-tolerated at the maximum tolerated dose, and induced protocol-defined aLA-specific T‑cell responses in 74% of the 35 participants across three cohorts (early-stage TNBC post-surgery, BRCA mutation prophylactic mastectomy, and TNBC combined with pembrolizumab); combination dosing with Merck’s Keytruda sustained antigen-specific T‑cell responses without new safety signals. The vaccine, developed with Cleveland Clinic and funded by the U.S. Department of Defense, will be followed for five years with ongoing IHC analyses to correlate aLA expression with response, and the company plans a Phase 2 neoadjuvant combination study with Keytruda to evaluate efficacy and long-term protection. ANIX has traded between $2.07 and $5.46 over the past year; the stock closed at $4.80 (down 6.43%) and was trading up overnight at $4.95 (+3.12%).

Analysis

Anixa Biosciences reported final Phase 1 results for its alpha-lactalbumin (aLA) breast cancer vaccine presented at SABCS showing the study met all primary endpoints and was safe and well-tolerated at the maximum tolerated dose in 35 participants across three cohorts (early-stage TNBC post-surgery, BRCA mutation prophylactic mastectomy candidates, and TNBC patients receiving adjuvant pembrolizumab). The vaccine elicited protocol-defined, aLA-specific T‑cell responses in 74% of participants, and combination dosing with Merck’s Keytruda maintained antigen-specific T‑cell responses without introducing new safety signals. The program is developed with the Cleveland Clinic and funded by the U.S. Department of Defense, and participants will be followed for five years while IHC analyses are ongoing to correlate tumor aLA expression with immune response and clinical benefit.

Management announced plans for a Phase 2 neoadjuvant combination study with Keytruda to assess efficacy and long-term protection, marking a clear clinical development pathway. Market reaction was muted-to-positive: ANIX has a 12‑month trading range of $2.07–$5.46, closed at $4.80 (down 6.43%) and traded up to $4.95 (up 3.12%) overnight, consistent with the mildly positive sentiment signal. Key near-term risks remain the small sample size, absence of demonstrated clinical efficacy endpoints to date, and dependence on Phase 2 outcomes and IHC correlation to de‑risk the program.

Key Decisions for Investors

• Consider initiating a modest, event‑driven exposure to ANIX ahead of Phase 2 enrollment given positive Phase 1 safety and immune-response signals, but size positions conservatively due to the small Phase 1 sample and binary clinical risk
• Monitor three specific near-term catalysts closely: publication of IHC correlation results, formal Phase 2 trial design and initiation details with Keytruda, and interim safety/efficacy readouts; use these events to scale in or out of positions
• Maintain downside protection or hedges (options or position limits) until Phase 2 demonstrates clinical efficacy or durable immune‑correlates are validated, because market re-rating hinges on positive efficacy data